(NASDAQ: TARS) Tarsus Pharmaceuticals's forecast annual revenue growth rate of 146.25% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.5%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.23%.
Tarsus Pharmaceuticals's revenue in 2023 is $16,154,000.On average, 2 Wall Street analysts forecast TARS's revenue for 2023 to be $160,833,294, with the lowest TARS revenue forecast at $105,621,864, and the highest TARS revenue forecast at $216,044,723. On average, 3 Wall Street analysts forecast TARS's revenue for 2024 to be $3,096,267,616, with the lowest TARS revenue forecast at $2,195,921,238, and the highest TARS revenue forecast at $4,540,406,563.
In 2025, TARS is forecast to generate $6,433,945,206 in revenue, with the lowest revenue forecast at $5,457,129,665 and the highest revenue forecast at $7,646,116,134.